This activity is jointly provided by Global Education Group and Physicians' Education Resource®, LLC (PER®)
This activity is supported by an educational grant from Amgen.
On-demand Medical Crossfire® activity
James A. Underberg, MD, MS, FACPM, FACP, FNLA
Clinical Assistant Professor of Medicine, NYU Medical School and NYU Center for CV Prevention
New York, New York
Henry N. Ginsberg, MD
Irving Professor of Medicine, Columbia University College of Physicians and Surgeons
New York, New York
Alan Brown, MD, FACC, FNLA
Director, Division of Cardiology, Advocate Lutheran General Hospital
Park Ridge, Illinois
Michael Davidson, MD
Professor, Director of the Lipid Clinic, The University of Chicago Pritzker School of Medicine
This activity is designed to update clinicians on the identification and diagnosis, as well as current guidelines and emerging algorithms for the treatment of statin intolerant patients. The efficacy and safety of current and emerging therapies for statin intolerant patients will also be reviewed. Expert faculty will discuss the true incidence and diagnostic criteria of statin intolerance, the mechanistic rationale for lowering LDL-C through PCSK9 inhibition and other novel targets/pathways, treatment strategies, and where emerging therapies fit into current treatment guidelines and algorithms. Learners have the opportunity to a gain practical clinical perspective from an expert roundtable discussion on a statin intolerant patient case. This activity is expected to improve lipid management of patients at increased ASCVD risk, particularly those with statin intolerance. The discussions will demonstrate how clinicians approach patient cases and treatment decisions, with their commentary, analysis, and recommendations for best practices in hypercholesterolemia.
After completing this activity, the participant should be better able to:
Apply recent guidelines on lipid management and strategies for effective management of individuals requiring drug therapy for hypercholesterolemia, particularly those in whom the response to maximally tolerated statin monotherapy may be inadequate
Articulate the practicalities of PCSK-9 administration, including potential for use as replacement or complementary treatment for patients on a statin and patient selection for use of these drugs
Release Date: 6/29/17
Expiration Date: 6/29/18
The educational design of this activity addresses the needs of lipidologists, cardiologists, endocrinologists, primary care physicians, NPs, and other allied health professionals with an interest in the diagnosis and management of hypercholesterolemia.
Segment 1: Practical Strategies for Diagnosing and Managing Statin Intolerant Patients in Your Practice
Segment 3: PCSK9 Inhibitors in Practice: Efficacy, Safety, Barriers, and Benefits
Segment 4: Practical Application of PCSK9 Inhibitors and Patient Guidance